Amarox

Patient Alert Card

XCARD (APIXABAN) 2.5mg, 5mg Tablets

Carry this card with you at all time

Show this card to your pharmacist, dentist and any other healthcare professionals that treat you.

This document is approved by the Executive Directorate of Pharmacovigilance at SFDA

Version no: 02

Oct 2023

➢ Information for PATIENTS

Take XCARD (APIXABAN) regularly as instructed, if you miss a dose, take it as soon as you remember and continue to follow your dosing schedule.

- Do not stop taking XCARD (APIXABAN) without talking to your doctor, as you are at risk of suffering from a stroke or other complications. (refer to the patient information leaflet)
- XCARD (APIXABAN) helps to thin your blood. However, this may increase your risk of bleeding.

Signs and symptoms of bleeding include bruising or bleeding under the skin, black or tar stools, blood in urine, nosebleed, dizziness, tiredness, paleness or weakness, sudden severe headache, coughing up blood or vomiting blood.

If the bleeding does not stop on its own, **immediately seek medical attention.**

If you need surgery, inform your doctor that you are taking XCARD (APIXABAN).

I am under anticoagulation treatment with XCARD (APIXABAN) to prevent blood clots

Patients and Health Care Professionals are asked to report any suspected adverse reactions via the national reporting system (Saudi Food & Drug Authority reporting system and MAH pharmacovigilance office).

Information for HEALTHCARE PROFESSIONALS

- XCARD (APIXABAN) is an oral anticoagulant acting by direct selective inhibition of factor Xa.
- XCARD (APIXABAN) may increase the risk of bleeding. In case of major bleeding events, it should be stopped immediately.
- Treatment with XCARD (APIXABAN) does not require routine monitoring of exposure. A calibrated quantitative anti-Factor Xa assay may be useful in exceptional situations, e.g., overdose and emergency surgery (prothrombin time (PT), international normalized ratio (INR) and activated partial thromboplastin time (aPTT) clotting tests are not recommended) - see SPC

Please complete this section or ask your doctor to do it

Name:
Date of Birth:
Indication:
Dose:
Doctor's Name:
Doctor's telephone:

Call for Reporting:
To report any suspected adverse reactions to, kindly contact:

National Pharmacovigilance Centre at Saudi Food and Drug Authority (SFDA):
SFDA call centre: 19999
E-mail: npc.drug@sfda.gov.sa
Website: https://ade.sfda.gov.sa

Marketing Authorization Holder Contact Information:

Saudi Amarox Industrial Company
Ms. Razan almalki
Pharmacovigilance Specialist
Al Jamiyah Street – Al Malaz – Riyadh Code 12629, Saudi Arabia.
Phone: +966 11 226 8850
Mobile: +966 531215235
Email: r.almalki@amaroxpharma.com